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Ab s t r Ac t
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a β-CoV, and a seventh member of family Coronaviridae causing infection in 
humans, are the causative agent of the new coronavirus disease 2019 (COVID-19). For the 1st time, the disease was reported as an outbreak 
on December 31, 2019 in Wuhan, Hubei Province, China, when patients with the symptoms of pneumonia were admitted in hospitals. Soon, 
the disease became epidemic and spread in 25 provinces in China with a total of 571 cases up to January 24, 2020. At present, COVID-19 has 
spread across 216 countries. As of July 18, 2020, the World Health Organization confirmed 13,876,441 cases and 593,087 deaths globally, 
despite rigorous containment and quarantine efforts. The main symptoms of COVID-19 include cough, fever, and fatigue and other symptoms 
such as headache, hemoptysis, sputum production, dyspnea, and diarrhea and lymphopenia may also arise. The diagnosis of COVID-19 is 
by demonstrating ribonucleic acid of SARS-CoV-2 in respiratory secretions by reverse transcription polymerase chain reaction. Treatment 
is supportive, and the role of antiviral agents is yet to be found. Preventive measures include regular and thorough cleaning of hands with 
soap and water for at least 20 s or an alcohol-based hand sanitizer and social distancing. It is important to develop simple, fast, and accurate 
technologies for the detection and treatment of COVID-19 to control the spread of the disease.
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In t r o d u c t I o n
Coronaviruses (CoV) are the group of viruses in the family 
Coronaviridae, causing sickness, which ranges from the common 
cold to deadly diseases such as Middle East respiratory syndrome 
(MERS) and severe acute respiratory syndrome (SARS). CoV are 
zoonotic being transmitted between animals and humans, 
whereby MERS transmitted from Arabian camels (dromedary) to 
humans and SARS transmitted from civet cats to humans. Novel CoV 
(nCoV) has emerged as a new virus strain not previously reported 
in humans. SARS-COV-2, a beta-CoV is the seventh member of the 
Coronaviridae family infecting humans and the causative agent of 
the new CoV disease, (COVID-19).[1] MERS, SARS-CoV-1, and SARS-
CoV-2 cause severe disease while four other viruses, namely, NL63, 
HKU1, 229E, and OC43, cause mild respiratory symptoms. The 
World Health Organization has declared new COVID-19, a Public 
Health Emergency of International concern.
The disease was reported on December 31, 2019, in Wuhan, 
Hubei Province, China, when 27 patients with the symptoms of 
pneumonia were admitted to hospitals. The clinical symptoms of 
the disease included dry cough, fever, and difficulty in breathing 
(dyspnea) and were related to Huanan Seafood Wholesale Market, 
Wuhan trading in wet animal and seafood including fish and live 
animals such as bats, poultry, marmots, and snakes.[2] On January 7, 
2020, the causative agent was identified and named as SARS-CoV-2 
by Chinese Centre for Disease Control and Prevention and disease 
named as new COVID-19 by the WHO on February 11, 2020.
or I g I n A n d glo b A l sc e n A r I o
The cases of COVID-19 were reported first in December 2019 in 
Wuhan, Hubei Province, China.[3] Up to December 29, 2019, five 
patients with acute respiratory distress syndrome (ARDS) were 
hospitalized, out of which one died.[4] Forty-one admitted hospital-
admitted patients were laboratory-confirmed for COVID-19 by 
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January 2, 2020. Some of the admitted patients had underlying 
diseases such as diabetes and hypertension, and they were 
presumed to be infected due to nosocomial infection. Chinese 
research authorities announced the isolation of a new virus from 
seafood market in Wuhan on January 7, 2020, which was named 
as 2019-nCoV. On January 13, 2020, one patient imported from 
Wuhan city of China was reported by the Ministry of Public 
Health Thailand, and on January 15, 2020, first case was reported 
in Japan by the Ministry of health, Labor, and Welfare of Japan. 
Subsequently, COVID-19 infection was spread to 25 provinces 
of China with total cases of 571 and 17 deaths up to January 22 
and 1975 confirmed cases and 56 deaths on January 25, 2020.[5] 
As of February 7, 2020, about 31,161 people have contracted the 
infection, and more than 630 people died in China, according to 
a report published in Nature (http://www.nature.com/articles/
d41586-020-00154) of infection. It is worth mentioning that a 
paper published in the year 2007 predicting the re-emergence of 
these viruses warned “The presence of a large reservoir of SARS-
CoV-like viruses in horseshoe bats, together with the culture of 
eating exotic mammals in Southern China, is a time bomb.”[6] It also 
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mentioned that “The possibility of the reemergence of SARS and 
other novel viruses from animals or laboratories and, therefore, the 
need for preparedness should not be ignored.”
United State of America confirmed the first case of COVID-19 
in America on January 23, 2020. Vietnam reported the first case 
of human to human transmission of SARS-CoV-2 on January 24, 
2020, and subsequently the second case was reported in Chicago 
on January 30, 2020 (WHO situation reports). On January 30, 
2020, the WHO declared COVID-19 a Public Health Emergency of 
International concern.
The WHO confirmed 375,498 COVID-19 cases and 16,362 
deaths on March 25, 2020, across 196 countries. The very next day, 
on March 26, 2020, 41,188 more confirmed cases were reported 
making it to 416,686 with 18,589 deaths across 197 countries, 
area, and territories including China, Italy, United States, Spain, 
Germany, Iran, France, South Korea, Switzerland, United Kingdom, 
The Netherlands, Austria, Belgium, Norway, Portugal, Sweden, 
Canada, Australia, Brazil, Denmark, Turkey, Malaysia, Israel, Czech 
Republic, Japan, Ireland, Ecuador, Luxembourg, Pakistan, Thailand, 
Poland, and India (WHO situation reports https://www.who.
int/emergencies/diseases/novel-coronavirus-2019/situation-
reports/). According to the WHO, the number of confirmed cases 
on March 25, 2020 was 3.5 times higher and the number of deaths 
4.2 times higher than that reported 15 days earlier on March 11, 
2020, globally [Figure 1]. As of now up to July 18, 2020, the World 
Health Organization (WHO) reported 13,876,441 confirmed cases 
and 593,087 deaths across 216 countries, area, and territories 
(WHO situation Report-180, https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/situation-reports/). At present, 
the highest COVID-19 infections are reported from the United 
States of America (3,544,143 confirmed cases and 137,674 deaths), 
followed by Brazil (2,012,151 cases and 76,688 deaths) and India 
(1,038,716 cases and 26,273 deaths). Despite rigorous containment 
and quarantine efforts, the number of COVID-19 cases is increasing 
at a fast rate globally.
st r u c t u r e A n d Phylo g e n e t I c An A lys I s o f 
sArs-coV-2
SARS-CoV-2, causative agent of novel COVID-19, has been classified 
as a β-CoV of group 2B by World Health Organization.[7,8] SARS-
COV-2 virion is spherical, enveloped and has spikes protruding 
from their surface like other CoV. The spike protein (S protein) of 
SARS-CoV-2 binds to the receptor angiotensin-converting enzyme 
2 (ACE2).[9] It is likely to bind 10–20 times more than the spikes of 
SARS virus of 2002 to ACE2 (NIH Research Matters, March 3, 2020, 
www.nih.gov). Although, the structure of spikes of the two viruses 
is similar, the antibodies against SARS were failed to bind to the 
spike protein of SARS-CoV-2, suggesting the treatment strategy 
based on antibodies and vaccination needs to be unique to SARS-
CoV-2. The highly variable spike protein of SARS-CoV-2 (COVID-
19) has been found to have a polybasic cleavage site at S1 and S2 
boundary through the insertion of 12 nucleotides, contributing to 
the prediction of three O-linked glycans around the cleavage site.[1]
The phylogenetic analysis indicates that SARS-CoV-2 (COVID-
19) belongs to beta CoV genus, including SARS-CoV that infects 
humans, bats, and wild animals as it showed more than 80% 
similarity with SARS-CoV and 50% similarity with MERS-CoV.[4,10,11] 
Due to insufficient phylogenetic difference between SARS-CoV-2 
and SARS-CoV, it can be considered as a new beta-CoV infecting 
humans. Genome sequences of SARS-CoV-2 (COVID-19) obtained 
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Figure 1: Coronavirus disease 19 confirmed cases and deaths globally during March-July, 2020. Further, there is tremendous increase in 
confirmed cases worldwide (Source: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
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from nine patients showed a 99.98% sequence similarity.[10] In an 
another study, it was found that SARS-CoV-2 from five patients 
showed 99.8–99.9% nucleotide similarity revealing the presence of 
a new beta-CoV strain.[4] SARS-CoV-2 is the seventh member of the 
family Coronaviridae known to infect humans and falls under the 
subfamily Orthocoronavirinae. It forms a clade with the subgenus 
sarbecovirus.[11] SARS-CoV-2 is most likely to be of bat origin, as 
evident due to the presence of high degree of similarity of ACE2 
receptor from a number of animal species, thereby implicating 
that these animals are the possible intermediate hosts for SARS-
Cov-2.[12,13] Furthermore, on gene 8, the virus has a single intact 
open reading frame 8, indicative of the bat origin of the virus.
tr A n s m I s s I o n
COVID-19 is thought to be zoonotic in origin based on the reports 
on the infected persons exposed to the wet animal market in Wuhan 
City, China. Some initial reports have identified two snake species 
as a possible reservoir of the SARS-CoV-2; however, no consistent 
evidence for CoV reservoirs other than birds and mammals is 
available.[14,15] Reports suggest that SARS-CoV-2 spreads mainly 
through person to person either between people who are in 
close contact with one another or through respiratory droplets 
produced due to coughing and sneezing of an infected person.[16] 
The droplets may enter inside the nose or mouth of nearby people 
or possibly be inhaled into the lungs. The virus is also thought to 
spread due to contact with infected objects or surfaces. Virus enters 
inside when a person touches mouth, nose, or eyes after coming in 
contact with the infected surface or object. A person is thought to 
be most contagious when they are symptomatic, however, some 
spread might be possible before people show symptoms according 
to the information shared on CDC website (https://www.cdc.gov/
coronavirus/2019-ncov/prepare/transmission.html). 
A report also mentioned the detection of the ribonucleic acid 
(RNA) of SARS-CoV-2 in blood and stool specimens.[17] Although, 
live virus from stool samples has been cultured.,[18] the fecal-oral 
transmission does not seem to be a significant factor in the spread 
of infection according to a joint WHO-China report on joint Mission 
on COVID, February 16–24, 2019.
Two small studies provide evidence, though drawn from 
limited data that vertical transmission of COVID-19 did not occur. 
The first report mentioned that the nine mothers with COVID-19 
delivered healthy infants through cesarean section.[19] The fluid 
surrounding infants in the womb as well as mother’s breast milk 
were also tested negative for SARS-CoV-2. The second case study 
carried out in Wuhan, China, mentioned that the infants born to 
COVID-19 positive women were tested negative for the disease.[20] 
The infants did not develop serious symptoms of cough, fever, 
diarrhea, or abnormal radiologic or hematologic evidence.
During a study on the stability of SARS-CoV-2 in aerosol and 
different surfaces, it was found that the virus is more stable on 
plastics and stainless steel compared to cardboard or copper.[21] 
The virus remained viable in air for the entire 3 h experiment while 
no viable virus was detected on the cardboard surface after 24 h 
and on the copper surface after 4 h. The virus was detected even 
after 72 h on stainless steel and plastic surfaces.
sym P to m s A n d dI Ag n o s I s
Most common symptoms of COVID-19 include cough, 
fever, and fatigue and other symptoms such as headache, 
hemoptysis, sputum production, dyspnea, and diarrhea and 
lymphopenia.[4,18,22] According to CDC, the symptoms generally 
appear after an incubation period of approximately 2–14 days 
after exposure. The time period from the onset disease symptoms 
to death generally ranges from 6 to 41 days, being dependent on 
the age and immune status of the patient.[18] In general, this time 
period is short in patients aged more than 70 years. In a study, it 
was found that clinical feature of COVID-19 by chest computed 
tomography scan is presented as pneumonia, however, some 
other features including ARDS, acute cardiac injury, RNAaemia, 
and grand-glass opacities incidence were also observed.[22] It 
was also shown that COVID-19 exhibits unique clinical features 
like targeting of the lower airway as evident by the symptoms 
of sneezing, rhinorrhea, and sore throat. In addition, some cases 
showed an infiltrate in the upper lobe of the lungs associated with 
dyspnea as evident from the chest radiographs.[23]
COVID-19 possibility should be considered primarily in 
patients with new-onset of fever and/or cough and dyspnea. 
In addition, it should also be important to consider the patients 
with lower respiratory tract illness without any clear cause. The 
likelihood of COVID-19 increases if the patient resides in or has 
traveled to a location where there is community transmission of 
SARS-Cov-2 prior 14 days; or had a close contact with a COVID-
19 suspected or confirmed case prior 14 days. The patients with 
the highest priority for testing include: Critically ill patients with 
unexplained pneumonia or respiratory failure; individuals in close 
contact with COVID-19 laboratory-confirmed patients within 
14 days of symptoms; individuals traveled within 14 days of 
symptoms onset to areas with sustained community transmission; 
immune-compromised individuals with fever or lower respiratory 
tract illness; and individuals critical to the pandemic response, 
including healthcare workers, public health officials, and other 
essential leaders with symptoms of fever or lower respiratory tract 
illness. A nasopharyngeal swab specimen is collected for testing 
SARS-CoV-2 as recommended by the CDC. RNA of SARS-CoV-2 
is detected by reverse transcription-polymerase chain reaction 
(RT-PCR) and a positive test generally confirms the diagnosis of 
COVID-19, though false-positive tests are also possible. WHO 
recommends re-sampling, if the test is negative, but suspicion 
of COVID-19 is there (https://www.who.int/emergencies/
diseases/novel- coronavirus-2019/technical - guidance/
surveillance-and-case-definitions).
PAt h o g e n e s I s
COVID-19 patients exhibit clinical manifestations similar to SARS-
CoV and MERS-CoV, including non-productive cough, fever, 
dyspnea (shortness of breath), myalgia (muscle pains), fatigue, 
normal or decreased leukocyte counts, and pneumonia.[22,24] In a 
case study, a female patient with a 5 days fever history presented 
with cough, coarse breathing sounds, and fever (39.0°C) was found 
positive for COVID-19 infection after carrying out the RT-PCR of 
patient’s sputum.[25] Leukopenia with white blood cell count of 
2.91 × 109 cells/L was observed in laboratory studies. In addition, 
C-reactive protein level of 16.16 mg/L in blood and high erythrocyte 
sedimentation rate was observed. In another study, it was found 
that in 41 laboratory-confirmed COVID-19 patients, complications 
mainly included ARDS in 29% patients, RNAaemia in 15% patients, 
acute cardiac injury in 12%, and secondary infection in 10% 
patients.[22] The report showed ARDS as the main death cause of 
COVID-19 patients. Uncontrolled systemic inflammatory response 
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due to the release of large amounts of pro-inflammatory cytokines 
and chemokines by immune effector cells on SARS-CoV infection 
is one of the main mechanisms for ARDS.[22,26,27] Likewise, a 50-year-
old man admitted to hospital presented with cough, fever, chills, 
fatigue, and shortness of breath with a travel history to Wuhan, 
China, was confirmed with COVID-19 by RT-PCR.[28] Histological 
examination revealed bilateral diffuse alveolar damage and ARDS 
indicating that the COVID-19 pathological features resemble 
SARS-CoV and MERS-CoV infection.[28] The pathogenesis of new 
COVID-19 is not understood fully yet, the mechanisms of SARS-
CoV and MERS-CoV could provide information on SARS-CoV-2 
pathogenesis to give an insight into COVID-19.
tr e At m e n t st r At e g I e s A n d Pr e c Au t I o n s
The US Food and Drug Administration has not approved any drug, 
so far, for treating the patients with COVID-19. According to the 
Centers for Disease Control and Prevention, clinical management 
comprises: Prevention of infection, control measures, and 
supportive care, including supplementary oxygen and mechanical 
ventilator support.
Treatment is based on multiple principals, including fusion 
inhibitors, replication disruption, suppressing the excessive 
inflammatory response, plasma treatment. Multiple drug 
candidates are presently being used and need further investigation. 
A trial of lopinavir and ritonavir to treat COVID-19 adult patients 
was carried out, where out of 199 patients 99 were included in 
lopinavir–ritonavir group and the other 100 in the standard-care 
group.[29] It was observed that no benefit was found with lopinavir–
ritonavir treatment compared to standard care as the mortality at 
28 days was similar in both the groups. Lopinavir-ritonavir is under 
investigation in one of the World Health Organization study.
Hydroxychloroquine and chloroquine, antimalarial oral drugs 
have shown in vitro activity against SARS-CoV-2, and other CoV, 
with relatively higher potency shown by hydroxychloroquine 
against SARS-CoV-2.[30-32] In China, chloroquine was used as a 
recommended antiviral for treating COVID-19 patients after a 
study reporting the clinical and virologic benefits of the drug.[33] 
Chloroquine or hydroxychloroquine are being used currently in 
treating hospitalized COVID-19 patients in many countries, based 
on in vitro and anecdotal data. Both the drugs have been reported 
to be well tolerated by COVID-19 patients. Hydroxychloroquine 
has been administered to COVID-19 hospitalized patients in 
many countries because of its higher in vitro activity against 
SARS-CoV-2 and availability compared to chloroquine. A study 
reported that with the use of hydroxychloroquine in combination 
with azithromycin or alone has decreased the detection of 
RNA of SARS-CoV-2 in the upper respiratory tract specimens as 
compared to a control group.[34] A caution is being advised in using 
hydroxychloroquine and azithromycin in patients with chronic 
conditions including renal failure and hepatic disease or those 
receiving medications that might interact to cause arrhythmias. 
At present, hydroxychloroquine is under testing in clinical trials 
for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 
infection, and treating patients with mild, moderate, and severe 
COVID-19.
In addition, remdesivir, an intravenous drug having broad-
spectrum antiviral activity due to the premature termination of 
RNA transcription leading to the inhibition of viral replication, 
has found to have in vitro activity against SARS-CoV-2 and in vitro 
and in vivo activity against related beta CoV.[32,35] Likewise, many 
other drugs are currently being considered for clinical trials or 
under investigation in clinical trials for the treatment of COVID-19 
worldwide. However, the main focus is on remdesivir; chloroquine 
and hydroxychloroquine; two HIV drugs, lopinavir and ritonavir; 
and the same combination along with interferon-beta (https://
www.sciencemag.org/news/2020/03/who-launches-global-
megatrial-four-most-promising-coronavirus-treatments). More 
laboratory and clinical evidence still need to be explored. World 
Health Organization is working to launch more than 80 clinical 
trials for the potential treatment of COVID-19.
In the present CoV pandemic, the use of convalescent plasma 
transfusion seems a promising treatment strategy until other 
treatment methods and vaccines are successfully evaluated. The 
administration of the convalescent plasma from a recovered 
patient within 14 days of onset of symptoms is the most promising. 
Clinical testing of the vaccine candidates against SARS-CoV2 is in 
progress.
The precautions include: Regular and thorough cleaning of 
hands with soap and water for at least 20 s or an alcohol-based 
hand sanitizer; covering nose and mouth with tissue during 
coughing and sneezing, maintain a social distance of at least 1 
m when a person is coughing or sneezing, and self-isolation or 
staying at home if one feels unwell. A person should not touch his 
eyes, mouth, or nose if the hands are not clean.
co n c lu s I o n
SARS-CoV-2, the causative agent of the new COVID-19, has become 
a pandemic affecting 211 countries and territories. SARS-CoV-2 is 
highly infectious being transmitted by close contact and droplets. 
The disease has posed a serious threat to mankind globally. 
Stringent measures are required to control its spread by reducing 
person to person transmission mainly in children, elderly people, 
and healthcare workers. It is important to develop simple, fast, and 
accurate technologies for the detection and treatment of COVID-
19 to control the spread of the disease. Many countries have now 
implemented major prevention and control measures including 
travel screenings to control further spread of the virus. The World 
Health Organization is working to assess the current level of 
knowledge about the new virus, provide advice, coordinate with 
partners, help countries prepare, increase supplies, and manage 
expert networks.
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